Float Short %

78.8

Margin Of Safety %

Put/Call OI Ratio

0.33

EPS Next Q Diff

0.04

EPS Last/This Y

0.09

EPS This/Next Y

0.22

Price

2.63

Target Price

11.4

Analyst Recom

Performance Q

-15.92

Relative Volume

0.55

Beta

-0.01

Ticker: IBRX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	IBRX	2.66	0.33	0.16	204501
2025-06-03	IBRX	2.7	0.33	0.10	208415
2025-06-04	IBRX	2.92	0.32	0.24	211045
2025-06-05	IBRX	2.9	0.32	0.41	214778
2025-06-06	IBRX	3.14	0.32	0.51	217327
2025-06-09	IBRX	3.44	0.33	0.31	223792
2025-06-10	IBRX	3.34	0.34	0.18	231611
2025-06-11	IBRX	3.22	0.34	0.33	233796
2025-06-12	IBRX	3.17	0.34	0.50	236178
2025-06-13	IBRX	3.07	0.34	0.17	238252
2025-06-16	IBRX	3.12	0.35	0.20	238743
2025-06-17	IBRX	2.84	0.35	0.34	239899
2025-06-18	IBRX	2.84	0.34	0.22	242421
2025-06-20	IBRX	2.87	0.34	0.27	243319
2025-06-23	IBRX	2.76	0.33	0.24	223951
2025-06-24	IBRX	2.78	0.33	0.31	227162
2025-06-25	IBRX	2.76	0.33	0.45	227600
2025-06-26	IBRX	2.78	0.33	0.90	228340
2025-06-27	IBRX	2.69	0.33	0.57	228807
2025-06-30	IBRX	2.64	0.33	0.36	229374
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	IBRX	2.66	-	10.5	-0.49
2025-06-03	IBRX	2.71	-	8.9	-0.49
2025-06-04	IBRX	2.92	-	-5.1	-0.49
2025-06-05	IBRX	2.90	-	14.5	-0.49
2025-06-06	IBRX	3.14	-	-6.2	-0.49
2025-06-09	IBRX	3.44	-	-9.0	-0.49
2025-06-10	IBRX	3.33	-	19.6	-0.49
2025-06-11	IBRX	3.22	-	20.6	-0.49
2025-06-12	IBRX	3.19	-	15.8	-0.49
2025-06-13	IBRX	3.07	-	21.3	-0.49
2025-06-16	IBRX	3.12	-	8.5	-0.49
2025-06-17	IBRX	2.84	-	33.9	-0.49
2025-06-18	IBRX	2.84	-	12.6	-0.49
2025-06-20	IBRX	2.87	-	9.9	-0.49
2025-06-23	IBRX	2.76	-	20.9	-0.49
2025-06-24	IBRX	2.78	-	10.6	-0.49
2025-06-25	IBRX	2.76	-	14.7	-0.49
2025-06-26	IBRX	2.78	-	10.6	-0.49
2025-06-27	IBRX	2.70	-	19.5	-0.49
2025-06-30	IBRX	2.63	-	18.0	-0.49
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	IBRX	0.00	53.63	80.31
2025-06-03	IBRX	0.00	53.63	80.31
2025-06-04	IBRX	0.00	53.63	80.31
2025-06-05	IBRX	0.00	53.63	80.31
2025-06-06	IBRX	0.00	53.63	80.31
2025-06-09	IBRX	0.00	53.68	80.31
2025-06-10	IBRX	0.00	53.68	80.31
2025-06-11	IBRX	0.00	53.68	78.54
2025-06-12	IBRX	0.00	53.68	78.54
2025-06-13	IBRX	0.00	53.68	78.54
2025-06-16	IBRX	0.00	53.68	78.54
2025-06-17	IBRX	0.00	53.68	78.54
2025-06-18	IBRX	0.00	53.68	78.54
2025-06-20	IBRX	0.00	53.68	78.54
2025-06-23	IBRX	0.00	53.68	78.54
2025-06-24	IBRX	0.00	53.68	78.54
2025-06-25	IBRX	0.00	53.68	78.54
2025-06-26	IBRX	0.00	53.68	78.80
2025-06-27	IBRX	0.00	53.68	78.80
2025-06-30	IBRX	0.00	53.68	78.80
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.15

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.11

Insider Transactions

Institutional Transactions

53.68

Beta

-0.01

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

93.6

Max Drawdown 5-Year %

Target Price

11.4

P/E

Forward P/E

PEG

P/S

74.64

P/B

P/Free Cash Flow

EPS

-0.58

Average EPS Est. Cur. Y

-0.49

EPS Next Y. (Est.)

-0.27

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1310.3

Relative Volume

0.55

Return on Equity vs Sector %

45.3

Return on Equity vs Industry %

64.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

ImmunityBio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 671

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

stock quote shares IBRX – ImmunityBio, Inc. Stock Price stock today

news today IBRX – ImmunityBio, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch IBRX – ImmunityBio, Inc. yahoo finance google finance

stock history IBRX – ImmunityBio, Inc. invest stock market

stock prices IBRX premarket after hours

ticker IBRX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IBRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y